Hematological Disease
Strategic Direction and Overarching Themes for the Service
(Site under construction)
Description of Programs and Protocols within the Service
Principal Investigator: John P. Plastaras, M.D., Ph.D.
Coordinator:
Office:
UPCC#: 04418
This is a Phase II single-arm, single-site, open label clinical trial with r/r HL patients, aimed to determine whether a RadVax approach using low-dose RT added to Nivolumab can improve response among patients who do not achieve a CR to nivolumab alone. The long-term goal is to develop an effective regimen for r/r HL patients.